"She is a little warrior, she is so strong. Within the last 12 months we found she has regressed even more. Isla is literally ...

At Neurogene, the developer of a gene therapy for Rett syndrome, expediency seems to be the priority, @adamfeuerstein writes.

Neurogene's stock price collapsed by 34.8% in pre-market trading after announcing data from the Phase I/II Rett syndrome ...

Neurogene has reported encouraging efficacy results with its gene therapy for rare genetic disorder Rett syndrome, but ...

Analysts did not seem very concerned by the treatment-related serious adverse event, noting that NGN-401 was well-tolerated ...

Neurogene (NASDAQ: NGNE) stock just took a sharp dive, plummeting 44% in a single day. Bad news on Monday caused the ...

Taysha Gene Therapies, Inc. is a clinical-stage biotechnology company focusing on adeno-associated virus (AAV)-based gene therapies for severe monogenic diseases of the central nervous system, with a ...

Biotech stock Neurogene collapsed Tuesday after a patient experienced a serious side effect in the company's Rett syndrome ...

Neurogene reports interim Phase 1/2 trial results for NGN-401 gene therapy in treating pediatric Rett syndrome, showing ...

Neurogene (NGNE, Financials) shares fell 35% in Tuesday's pre-market trading following the release of interim results from a ...

The company has made significant advancements in its discussions with the FDA regarding the Rett syndrome study, focusing on functional gains and restoration of milestones as key endpoints. This ...